Compare CAKE & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAKE | VERA |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.5B |
| IPO Year | 1992 | 2021 |
| Metric | CAKE | VERA |
|---|---|---|
| Price | $49.82 | $49.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $57.87 | ★ $67.67 |
| AVG Volume (30 Days) | 1.0M | ★ 1.8M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 24.69 | N/A |
| EPS | ★ 3.29 | N/A |
| Revenue | ★ $3,711,211,000.00 | N/A |
| Revenue This Year | $6.51 | N/A |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | $15.16 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $42.69 | $18.53 |
| 52 Week High | $69.70 | $50.16 |
| Indicator | CAKE | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 83.43 |
| Support Level | $46.47 | $40.38 |
| Resistance Level | $48.89 | $47.10 |
| Average True Range (ATR) | 1.20 | 3.35 |
| MACD | 0.60 | 1.34 |
| Stochastic Oscillator | 90.17 | 99.33 |
Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.